论文部分内容阅读
目的:分析用马来酸曲美布汀联合黛力新治疗肠易激综合征的临床疗效。方法:对2010年10月～2011年10月期间我院收治的156例肠易激综合征患者的临床资料进行回顾性研究。我们将这156例患者随机分成对照组和观察组,对照组有76例患者,观察组有80例患者。对照组的76例患者单独使用马来酸曲美布汀进行治疗,为观察组的80例患者在使用马来酸曲美布汀的基础上,加用黛力新进行治疗。治疗结束后,对两组患者的治疗效果、发生不良反应的情况进行比较。结果:经过1个月的治疗,观察组患者治疗的总有效率为91.25%,对照组患者治疗的总有效率为55.26%。观察组患者治疗的总有效率明显高于对照组患者,二者相比差异具有显著性(p<0.05)。观察组患者SDS评分和HAMD评分的改善情况明显好于对照组患者,二者相比差异具有统计学意义(p<0.05)。在治疗过程中,观察组患者发生不良反应的几率为5%,对照组中没有发生不良反应的患者,二者相比差异无显著性(p>0.05)。结论:用马来酸曲美布汀联合黛力新治疗肠易激综合征的疗效显著,可有效地改善患者的消化道症状和不良情绪,值得在临床上推广使用。
Objective: To analyze the clinical efficacy of trimebutine maleate combined with Deanin in the treatment of irritable bowel syndrome. Methods: The clinical data of 156 patients with irritable bowel syndrome admitted to our hospital from October 2010 to October 2011 were retrospectively studied. We randomly divide the 156 patients into control and observation groups, with 76 patients in the control group and 80 patients in the observation group. Sixty-six patients in the control group were treated with trimebutine maleate alone. Eighty patients in the observation group were treated with trimebutine maleate on the basis of trimebutine maleate. After treatment, the two groups of patients treated with adverse reactions were compared. Results: After 1 month of treatment, the total effective rate of treatment in observation group was 91.25%, and that in control group was 55.26%. The total effective rate of observation group was significantly higher than that of the control group, the difference was significant (p <0.05). The improvement of SDS score and HAMD score in observation group was significantly better than that in control group, the difference was statistically significant (p <0.05). In the course of treatment, patients in the observation group had a 5% incidence of adverse reactions, while patients in the control group had no adverse reactions. There was no significant difference between the two groups (p> 0.05). Conclusion: Trimebutine maleate combined with Deanxit treatment of irritable bowel syndrome has a significant effect, which can effectively improve the patient’s gastrointestinal symptoms and adverse emotions, it is worth promoting in clinical use.